METHODS AND MATERIALS FOR ASSESSMENT OF RESPONSE TO THERAPY AGAINST PLASMA-BLASTS AND PLASMA CELLS Russian patent published in 2023 - IPC A61K39/395 A61P19/02 A61P37/00 G01N33/53 

FIELD: pharmaceutics; medicine.

SUBSTANCE: invention relates to the field of pharmaceutics and medicine, namely to a method for the treatment of a disease in a patient, including: a) measurement of a level of CD38-expressing cells in a patient compared to a reference individual without a disease, where CD38-expressing cells are plasma-blasts and plasmacytes; and b) administration to the patient of therapeutically effective amount of an anti-CD38 antibody, where the disease is an autoimmune disease, and, after treatment with an anti-CD20 antibody, an increased level of CD38-expressing cells was detected in the patient compared to the reference individual, and where, in a biological sample obtained in the patient after treatment with the anti-CD20 antibody, the following was detected: i) an increased level of CD38-expressing plasma-blasts and plasmacytes compared to the reference subject, when analyzing free light chains of Ig, and ii) the presence of an increased level of at least one gene increased in CD38-expressing cells compared to the reference individual.

EFFECT: use of an anti-CD38 antibody for the treatment of patients, when measuring plasma-blasts and plasma cells before the treatment of patients suffering from an autoimmune disease, which cannot reach remission of the disease, using therapy based on an anti-CD20 antibody.

17 cl, 20 dwg, 6 tbl, 21 ex